I followed up with IR last Friday and received response yesterday. It seems that hitting 250 events is not necessarily the BETonMACE end of trial trigger and that the "adaptive trial" allows them to subjectively end the trial anytime at or after 250. Based on the vague event number updates in the recent corporate presentation, it is possible (I'm not saying likely) that they have already met or exceeded 250 events and could make the call to end dosing and start trial wrap up any day now.

I stated: "I notice that you repeatedly use the phrase "250+ narrow events" when my questions specifically ask about the 250 event goal. Once 250 narrow events are adjudicated, can the trial still continue? In other words, is the trigger for trial completion reaching 250 adjudicated narrow events, or does Resverlogix and the clinical team have the option/discretion to continue dosing after 250 narrow events have been adjudicated?"

Answer from Sarah: "As stated in previous presentations, we have options as BETonMACE is an adaptive trial. The current plan is once we reach 250+ narrow MACE (meaning, 250 at min.) we’ll look to wind down the trial. By the time adjudication is complete, we’ll likely end up with more events past 250."

In other news, coming up on March 19 will be the 1 year anniversary of exceeding full enrollment, at which time all patients will have been dosed for at least 1 year! Of course, those that died or discontinued are excluded. One caveat is that last handful of no more than 25 China patients that enrolled after through end of June 2018.

BearDownAZ